title: Definitive conformal radiotherapy for localized high-risk prostate cancer: a long-term follow-up study with PSA course.
abstract: BACKGROUND
  The present study investigated the long-term outcome of patients with localized high-risk prostate cancer after definitive conformal radiotherapy.
  
  
  METHODS
  Ninety-one consecutive patients with stage T1-T4 prostatic carcinoma were treated from 1996 through 2000. Each patient had at least one of the following risk factors: stage > T2b (UICC 1997; 55 patients), Gleason score > 7 (24 patients), or pre-treatment PSA > 20 ng/mL (40 patients). All patients received a conformal radiotherapy of the prostate (median dose, 70 Gy), eighty-three patients (91%) combined with temporary androgen deprivation (median duration, 4 months). All patients were followed continuously during a median of 5.2 years (range, 0.9 to 8.8 years). Biochemical failure after irradiation was defined as a PSA greater than 0.4 ng/mL and three consecutive serum PSA elevations.
  
  
  RESULTS
  The 5- and 7-year overall survival rates were 86% and 74%, respectively. The 5- and 7-year biochemical disease-free survival (bDFS) rates were 78% and 66% respectively. The most important predictors of bDFS were Gleason score and central axis dose of 70 Gy or higher. PSA nadir (median, 0.1 ng/mL) was not predictive of subsequent biochemical disease-free survival.
  
  
  CONCLUSIONS
  Our study confirms the findings of others and encourages us to proceed with this treatment policy for T1-T4 high-risk prostate cancer modified by using higher doses and long-term androgen deprivation.
authors.affiliation: Department of Radiotherapy, Hannover Medical School, Hannover, Germany. Bruns.Frank@MH-Hannover.de
authors.forename: Frank
authors.initials: F
authors.lastname: Bruns
authors.forename: Cordula
authors.initials: C
authors.lastname: Franzki
authors.forename: Gerd
authors.initials: G
authors.lastname: Wegener
authors.forename: Johann H
authors.initials: JH
authors.lastname: Karstens
mesh_terms: D000726:Androgen Antagonists / Q000627:therapeutic use; D003131:Combined Modality Therapy; D018572:Disease-Free Survival; D005500:Follow-Up Studies; D006801:Humans; D053208:Kaplan-Meier Estimate; D008137:Longitudinal Studies; D008297:Male; D009367:Neoplasm Staging; D017430:Prostate-Specific Antigen / Q000097:blood*; D011471:Prostatic Neoplasms / Q000097:blood* / Q000473:pathology / Q000532:radiotherapy*; D020266:Radiotherapy, Conformal; D012307:Risk Factors
chemical_list: D000726:Androgen Antagonists; D017430:Prostate-Specific Antigen